| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2017 | BE COOL PHARMACEUTICS LLC | 1764 TANANA LOOP, STE 424 | FAIRBANKS | AK | 99775-0001 | FAIRBANKS NORTH STAR | USA | R41HL135964 | Development of the first thermolytic to suppress shivering and seizure | 000 | 1 | NIH | 7/22/2022 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $0 ) |
| | 2020 | 2017 | BE COOL PHARMACEUTICS LLC | 1764 TANANA LOOP, STE 424 | FAIRBANKS | AK | 99775-0001 | FAIRBANKS NORTH STAR | USA | R41HL135964 | Development of the first thermolytic to suppress shivering and seizure | 000 | 1 | NIH | 9/10/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $158,435 ) |
| | 2019 | 2019 | BE COOL PHARMACEUTICS LLC | 970 WATER THRUSH DR | FAIRBANKS | AK | 99712-1451 | FAIRBANKS NORTH STAR | USA | R41HL135964 | Development of the first thermolytic to suppress shivering and seizure | 000 | 1 | NIH | 12/18/2018 | $103,435 |
| | 2019 | 2019 | BE COOL PHARMACEUTICS LLC | 1764 TANANA LOOP, STE 424 | FAIRBANKS | AK | 99775-0001 | FAIRBANKS NORTH STAR | USA | R41HL135964 | Development of the first thermolytic to suppress shivering and seizure | 002 | 1 | NIH | 4/23/2019 | $0 |
| | 2019 | 2019 | BE COOL PHARMACEUTICS LLC | 1764 TANANA LOOP, STE 424 | FAIRBANKS | AK | 99775-0001 | FAIRBANKS NORTH STAR | USA | R41HL135964 | Development of the first thermolytic to suppress shivering and seizure | 005 | 1 | NIH | 8/1/2019 | $0 |
| | 2019 | 2019 | BE COOL PHARMACEUTICS LLC | 1764 TANANA LOOP, STE 424 | FAIRBANKS | AK | 99775-0001 | FAIRBANKS NORTH STAR | USA | R41HL135964 | Development of the first thermolytic to suppress shivering and seizure | 004 | 1 | NIH | 8/1/2019 | $0 |
| | 2019 | 2019 | BE COOL PHARMACEUTICS LLC | 1764 TANANA LOOP, STE 424 | FAIRBANKS | AK | 99775-0001 | FAIRBANKS NORTH STAR | USA | R41HL135964 | Development of the first thermolytic to suppress shivering and seizure | 001 | 1 | NIH | 3/15/2019 | $55,000 |
| | 2019 | 2017 | BE COOL PHARMACEUTICS LLC | 1764 TANANA LOOP, STE 424 | FAIRBANKS | AK | 99775-0001 | FAIRBANKS NORTH STAR | USA | R41HL135964 | Development of the first thermolytic to suppress shivering and seizure | 003 | 1 | NIH | 8/1/2019 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $298,871 ) |
| | 2017 | 2017 | BE COOL PHARMACEUTICS LLC | 970 WATER THRUSH DR | FAIRBANKS | AK | 99712-1451 | FAIRBANKS NORTH STAR | USA | R41HL135964 | Development of the first thermolytic to suppress shivering and seizure | 000 | 1 | NIH | 8/29/2017 | $298,871 |
|
|
